XML 65 R55.htm IDEA: XBRL DOCUMENT
v3.22.1

Goodwill and Intangible Assets, Net - Narrative (Details) $ in Millions | 3 Months Ended |
--- | --- | ---
Mar. 31, 2022 USD ($) item product | Mar. 31, 2021 USD ($) | Dec. 31, 2021 USD ($)
Goodwill and Intangible Assets [Line Items] |  |  |
Amortization expense associated with definite-lived intangible assets | $ 14 | $ 15 |
Net Carrying Value | $ 498 |  | $ 512
Pharma Segment | Vivus |  |  |
Goodwill and Intangible Assets [Line Items] |  |  |
Number of approved therapies | item | 2 |  |
Number of product candidate in active clinical development | product | 1 |  |
Developed Technology |  |  |
Goodwill and Intangible Assets [Line Items] |  |  |
Net Carrying Value | $ 213 |  | $ 220

X
- Definition Goodwill and Intangible Assets [Line Items] + References No definition available. + Details
Name: | iep_GoodwillAndIntangibleAssetsLineItems
Namespace Prefix: | iep_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of approved therapies. + References No definition available. + Details
Name: | iep_NumberOfApprovedTherapies
Namespace Prefix: | iep_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of product candidate in active clinical development. + References No definition available. + Details
Name: | iep_NumberOfProductCandidateInActiveClinicalDevelopment
Namespace Prefix: | iep_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 20 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=iep_PharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=iep_VivusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |